Buprenorphine for Opioid Transition in Personal Injury Patients

James Wong — Founder & Pharmacist, LienScripts | August 22, 2024 | 7 min read

When a personal injury patient who was opioid-naive before an accident develops opioid dependence during injury treatment, that dependence is itself a compensable consequence of the accident. Buprenorphine is the most effective FDA-approved treatment for opioid use disorder — and its prescription record documents the full scope of the patient's injury.

[!KEY] When a patient who was opioid-naive before their accident develops opioid dependence during injury treatment, that dependence is a compensable consequence of the original injury — and the buprenorphine prescription record documents both its existence and its ongoing treatment burden.

When Injury Treatment Creates a New Medical Need

Most people who develop opioid dependence during personal injury treatment never intended to. They were injured in a car accident, a workplace incident, or a fall. Their physician prescribed opioids to manage acute or severe chronic pain — which was appropriate and medically necessary given the nature of the injury. Over weeks or months of use, they developed physical dependence on those opioids.

This is not a moral failure. It is a predictable pharmacological consequence of sustained opioid exposure, one that occurs in a meaningful proportion of patients who use opioids for extended periods. In California personal injury law, when a patient was opioid-naive before the accident — not using opioids or opioid agonists for any reason prior to the injury — and develops opioid dependence during the course of injury treatment, that dependence is a compensable consequence of the original accident.

The medication used to treat that dependence — buprenorphine — and the pharmacy record it creates, are directly relevant to the full scope of the patient's injury claim.

What Is Buprenorphine?

Buprenorphine is a partial mu-opioid receptor agonist. It binds to opioid receptors with high affinity but produces only partial activation — unlike full agonists such as oxycodone, hydrocodone, or morphine, which produce maximal receptor activation. This partial agonist property gives buprenorphine its therapeutic profile:

• Ceiling effect on respiratory depression: Unlike full agonists, buprenorphine's respiratory depression effect plateaus at moderate doses, significantly reducing overdose risk
• Sustained receptor occupancy: Buprenorphine's high receptor affinity and long half-life allow once-daily or twice-daily dosing
• Suppression of opioid withdrawal: By occupying opioid receptors continuously, buprenorphine prevents the withdrawal syndrome that occurs when full agonists are discontinued abruptly

Buprenorphine Formulations in PI Cases

Two distinct formulations of buprenorphine appear in personal injury pharmacy records, each serving a different clinical purpose:

Buprenorphine/Naloxone (Suboxone and Generics) — for Opioid Use Disorder

Suboxone combines buprenorphine with naloxone, an opioid antagonist. The naloxone component is added to deter misuse: when taken sublingually (under the tongue) as prescribed, naloxone has minimal absorption and does not counteract buprenorphine's effects. If someone attempts to inject the medication, the naloxone is absorbed rapidly and precipitates acute withdrawal — a powerful deterrent.

Suboxone is FDA-approved for opioid use disorder (OUD) and is the most commonly prescribed formulation for PI patients who have developed opioid dependence during injury treatment.

Buprenorphine Buccal Film (Belbuca) — for Chronic Pain

Belbuca is a buprenorphine buccal film formulation FDA-approved for chronic pain severe enough to require around-the-clock opioid analgesia. Unlike Suboxone, Belbuca is prescribed as a pain medication — its lower dose range is specifically designed for analgesia rather than OUD management.

Belbuca may appear in PI pharmacy records for patients whose severe, ongoing pain is being managed with buprenorphine as a safer alternative to full-agonist opioids, particularly in patients with documented histories of opioid sensitivity.

Both formulations may appear in the same patient's pharmacy record during the course of PI treatment.

What the Buprenorphine Record Documents for Attorneys

For attorneys handling personal injury cases where a client has been prescribed buprenorphine, the pharmacy record tells a specific and legally important story:

Pre-Injury Baseline

If the patient's pharmacy history shows no opioid prescriptions before the accident date, the subsequent appearance of full-agonist opioids followed by buprenorphine creates an unambiguous before-and-after narrative. The patient was opioid-naive. The accident occurred. Opioids were prescribed to manage injury pain. Opioid dependence developed. Buprenorphine was initiated to manage that dependence. The entirety of this sequence is causally linked to the original injury.

The Opioid Dependence as a Distinct, Compensable Injury

California courts have recognized that when a plaintiff sustains an injury in an accident, and that injury — or its prescribed treatment — causes additional physical harm, the additional harm is compensable. Opioid dependence developing during the medically necessary treatment of injury pain is compensable additional harm. The buprenorphine prescription is evidence of both the existence and the severity of this secondary injury.

[!KEY] Opioid dependence that develops during prescribed post-accident treatment is a separate, compensable injury — include buprenorphine treatment costs and future maintenance therapy projections in the damages calculation, documented by the pharmacy fill record and supported by the treating physician's clinical notes.

Ongoing Treatment Costs

Buprenorphine therapy for opioid use disorder is typically long-term. Clinical guidelines generally support extended treatment — often a year or more — because premature discontinuation significantly increases relapse risk. The ongoing prescription refill record documents the patient's continuing treatment burden and supports inclusion of those future treatment costs in the damages calculation.

Clinical Management of the Transition

The clinical process of transitioning a personal injury patient from full-agonist opioids to buprenorphine requires careful management by a physician with buprenorphine prescribing authority (DEA X-waiver or current DEA registration under updated regulations). The transition involves:

1. Reduction or cessation of the full-agonist opioid
2. Allowing the patient to enter mild-to-moderate withdrawal (to prevent precipitated withdrawal from buprenorphine's high receptor affinity)
3. Buprenorphine induction, typically in an office or home setting
4. Dose titration to clinical stability
5. Ongoing maintenance and monitoring

This process is documented in both the physician's records and the pharmacy dispensing records. Each step creates clinical documentation of the severity and medical complexity of the patient's opioid-related injury.

[!NOTE] Clinical guidelines support long-term buprenorphine maintenance — often a year or more — because premature discontinuation significantly increases relapse risk, and each refill documents the continuing treatment burden that supports inclusion of future costs in the damages calculation.

Pharmacy Lien Coverage for Buprenorphine

Buprenorphine formulations prescribed for opioid use disorder or chronic pain management resulting from injury treatment are covered under pharmacy liens with LienScripts when prescribed by a licensed, authorized treating physician. Both Suboxone/generics and Belbuca are eligible.

Because buprenorphine therapy is often long-term, consistent lien coverage throughout the maintenance period ensures the patient's treatment is never interrupted due to cost — important both for clinical outcomes and for maintaining the continuity of the pharmacy record.

[!KEY] A pre-accident pharmacy record showing no prior opioid use, followed by opioid prescribing post-accident, followed by buprenorphine initiation, creates a causation chain in the pharmacy record itself that is very difficult for defense to attribute to anything other than the accident-related treatment.

For attorneys with clients who are on buprenorphine as a result of their injury treatment, understanding this medication and its legal significance is essential to fully capturing the damages available in the case. Visit for attorneys to learn more about how LienScripts works with personal injury practices.

Related Resources

• Pharmacy Services for Personal Injury Clients: How It Works
• What Are Medication Liens?